From: Clinical and serological evaluation of a novel CENP-A peptide based ELISA
CENP-A | CENP-B | ||||||||
---|---|---|---|---|---|---|---|---|---|
No. (%) >1.0 RU | No. (%) >1.5 RU | Mean/Median RU | Min/Max RU | No. (%) >1.0 RU | No. (%) >1.5 RU | Mean/Median RU | Min/Max RU | t-test CENP-B vs. A | |
SSc (n = 131) | 64 (48.9) | 48 (36.6) | 2.37/0.98 | 0.1/7.9 | 53 (40.5) | 49 (37.4) | 2.77/0.47 | 0.2/9.6 | P = 0.27 |
SLE (n = 109) | 18 (16.5) | 4 (3.7) | 0.62/0.46 | 0.1/5.2 | 21 (19.3) | 6 (5.5) | 0.81/0.66 | 0.2/6.3 | P = 0.027* |
RA (n = 15) | 0 (0.0) | 0 (0.0) | 0.29/0.26 | 0.1/0.5 | 0 (0.0) | 0 (0.0) | 0.51/0.49 | 0.3/0.9 | P = 0.0002* |
Other SARD (n = 10) | 0 (0.0) | 0 (0.0) | 0.34/0.26 | 0.1/0.8 | 1 (10.0) | 1 (10.0) | 0.71/0.61 | 0.3/1.6 | P = 0.024* |
Controls all (n = 134) | 18 (13.4) | 4 (3.0) | 0.56/0.43 | 0.1/5.2 | 22 (16.4) | 7 (5.2) | 0.76/0.61 | 0.2/6.3 | P = 0.0047* |